Document is current
Any future updates will be listed below
-
Authors
Makkawi, Seraj
Abulaban, Ahmad
Al Malik, Yaser
Alshehri, Ebtesam
Althobaiti, Ahmed
Aljarallah, Salman https://orcid.org/0000-0003-0138-7924
Elboghdady, Ahmed
AlHajjar, Lynn
Shami, Sahar
Bohlega, Saeed
Aljumah, Mohammed https://orcid.org/0000-0002-9820-9579
-
Funding
Funding for this research was provided by:
Merck Serono Middle East
- License Information
-
More Information
Article History
Received: 20 October 2024
Accepted: 19 December 2024
First Online: 4 January 2025
Declarations
:
: Seraj Makkawi received an honorarium for attending the advisory board meeting on which this article is based. Also, he reports personal fees from Roche, Merck, Novartis, Sanofi Genzyme, Biogen, Janssen, Biologix, AstraZeneca, and Horizon Therapeutics outside the submitted work. Salman Aljarallah received an honorarium for attending the advisory board meeting on which this article is based. Also, he reports receiving speaker and consultation fees from Roche, Merck, Novartis, Sanofi Genzyme, Biogen, Janssen, Biologix, AstraZeneca, and Horizon Therapeutics outside the submitted work. All authors participated in the closed meeting that gave rise to this article, which was organized and supported by Merck Serono Middle East FZ-Ltd.
: The study did not involve human participants, human data, or human material; thus, ethics committee approval was not required. The panelists were all authors of this paper.
